News for Galapagos NV (GLPG)

Significant Stock Acquisition by TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) On February 28, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed

On February 25, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Acelyrin

Overview of the Recent Transaction Stonepine Capital Management, LLC (Trades, Portfolio), a prominent investment firm, recently made a strategic move by acquiri

**media[549023]**

On February 13, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant stock transaction involving Cargo Therapeutics Inc (CRGX). The firm

On February 18, 2025, Gilead Sciences, Inc. executed a significant stock transaction involving Arcus Biosciences Inc (RCUS). The firm added 9,630,525 shares of

On February 18, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 5,298,328 shares of Acelyrin Inc. This acqu

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) —

**media[542661]**

On February 7, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring 4,210,525 shares of Galapagos NV. This acqu

Galapagos (GLPG) stock dips as Morgan Stanley downgrades its rating to Underweight from Equal Weight amid its CAR-T therapy reprioritization. Read more here

Discover Galapagos NV's plans for GLPG5101 pivotal trials, SpinCo launch, and innovative therapies.

Galapagos NV (NASDAQ:GLPG) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSri Ramaswami - Senior Vice President and Global...

The following slide deck was published by Galapagos NV in conjunction with their 2024 Q4 earnings call.

On December 31, 2024, Prosight Management, LP (Trades, Portfolio) executed a significant transaction involving Vincerx Pharma Inc (VINC), reducing its holdings

Galapagos downgraded by Barclays, PT cut to €22

On January 8, 2025, Galapagos NV. announced its plans to split into two listed entities by mid-2025 by spinning off its activities focused on innovative medicines.

Belgium stocks higher at close of trade; BEL 20 up 0.27%

Belgium stocks higher at close of trade; BEL 20 up 0.81%